Hymecromone

Generic Name: Hymecromone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₈O_₃

CAS Number: 90-33-5

Unique Ingredient Identifier: 3T5NG4Q468

Indication: 用于胆囊炎、胆石症、胆道感染及胆囊术后综合征。

Associated Conditions: Biliary Dyskinesia, Dyspepsia, Gallbladder Inflammation, Gallstones, Biliary spasm, Mild, moderate Hepatic Insufficiency

Associated Therapies: -

Clinical Trials

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Phase 2

Not yet recruiting

Conditions: Lung Diseases, Interstitial
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis

Interventions: Drug: hymecromone

First Posted Date: 2024-03-22

Last Posted Date: 2025-01-08

Lead Sponsor: National Institute of Environmental Health Sciences (NIEHS)

Target Recruit Count: 37

Registration Number: NCT06325696

Locations: 🇺🇸
NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

Phase 2

Recruiting

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Hymecromone

First Posted Date: 2022-03-25

Last Posted Date: 2024-11-27

Lead Sponsor: Aparna Goel

Target Recruit Count: 24

Registration Number: NCT05295680

Locations: 🇺🇸
Stanford Clinic, Stanford, California, United States

A Study of Oral Hymecromone and Hyaluronan Synthesis

Phase 1

Completed

Conditions: Respiratory Disease
Healthy

Interventions: Drug: hymecromone

First Posted Date: 2016-05-23

Last Posted Date: 2021-06-16

Lead Sponsor: Paul Bollyky

Target Recruit Count: 12

Registration Number: NCT02780752

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy